eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
3/2020
vol. 12
 
Share:
Send email
Share:
abstract:
Original paper

Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval

Alexander A. Harris
1
,
Mark Korpics
2
,
Zohaib Sherwani
1
,
Ahmer Farooq
3
,
Kristin G. Baldea
3
,
Robert Flanigan
3
,
Matthew M. Harkenrider
3
,
Abhishek A. Solanki
1

  1. Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA,
  2. Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
  3. Department of Urology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA
J Contemp Brachytherapy 2020; 12, 3: 216–224
DOI: https://doi.org/10.5114/jcb.2020.96861
Online publish date: 2020/06/30
View full text Get citation
 
Introduction
High-dose-rate (HDR) brachytherapy is an effective method of treating localized prostate cancer. There are limited data on the relationship between implant interval and outcomes. This study aims to assess if the implant interval between HDR treatments has an impact on patient-reported health-related quality of life (QOL) and physician-graded toxicity in men treated for localized prostate cancer.

Material and methods
Patients were treated with HDR brachytherapy as monotherapy with 27 Gy in 2 fractions, given over two implants, performed 1-2 weeks apart. Patients were dichotomized into one-week and two-week cohorts. Patient-reported EPIC-26 genitourinary (GU), gastrointestinal (GI), and sexual QOL were assessed. Linear regression, chi-squared testing, and generalized linear mixed effect models were used to assess the differences in patient characteristics, patient-reported QOL, and physician-graded toxicity.

Results
Outcomes of 122 patients were analyzed. Median follow-up was 18 months. Patient-reported GU and GI QOL worsened after treatment with a return towards baseline over time, while patient-reported sexual QOL worsened after treatment, but did not return towards baseline. There were no differences in patient-reported health related QOL as a function of implant interval. Maximum physician-graded GU, GI, and sexual toxicity rates of grade 2 or 3 were 68%, 3%, and 53%, respectively. There was no difference in rates of grade 2 or 3 toxicity as a function of implants interval.

Conclusions
HDR brachytherapy for prostate cancer is a well-tolerated treatment. The interval between treatments is not associated with differences in patient-reported QOL or physician-graded toxicities.

keywords:

brachytherapy, prostate cancer, implant interval, patient-reported outcomes, quality of life, toxicity

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.